X

Drug Profile

Denibulin - MediciNova

Alternative Names: Denibulin di-hydrochloride; Denibulin-hydrochloride; MN-029

Latest Information Update: 12 May 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Angiogene Pharmaceuticals
Developer MediciNova
Class Antineoplastics; Benzimidazoles; Small molecules
Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Suspended Solid tumours

Most Recent Events

31 Dec 2020 Efficacy and adverse events data from a first phase I trial in Solid tumours released by MediciNova
31 Dec 2020 Efficacy and adverse events data from a second phase I trial in Solid tumours released by MediciNova
13 Jan 2016 MediciNova receives patent allowance for denibulin in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com